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Inﬂiximab is an effective treatment for sarcoidosis patients with persistent disease despite glucocorti-
coids and immunosuppressive therapy. Patients receiving inﬂiximab can experience side effects,
inducing an autoimmune reaction. Treatment is unclear for sarcoidosis patients who develop autoim-
mune reactions to inﬂiximab. We report a case of a patient with advanced sarcoidosis who developed a
myositis type reaction to inﬂiximab characterized by diffuse muscle achiness and weakness and marked
elevations in serum creatinine phosphokinase (CPK) and aldolase. Manifestations of sarcoidosis and
myositis improved after Acthar treatment. This is the ﬁrst report of successful treatment with Acthar in a
patient with advanced sarcoidosis with an autoimmune reaction to inﬂiximab.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Inﬂiximab has been effective for sarcoidosis patients with
persistent disease despite glucocorticoids and immunosuppressive
therapy [1]. Inﬂiximabmay lead to signiﬁcant side effects, including
the induction of an autoimmune reaction. Therapy is unclear for
patients who develop autoimmune reactions [2,3]. We report a
patient with advanced sarcoidosis who developed a myositis re-
action to inﬂiximab that was successfully treated with Acthar gel.2. Case report
In 1997 a 34-year-old African-American female patient was
diagnosed with sarcoidosis after presenting with shortness of
breath, cough, erythema nodosum on her legs, sinuses, uveitis, and
arthritis in legs and neck. Biopsies of her leg lesions and sinuses
demonstrated noncaseating granulomas, chest x-ray examination
revealed adenopathy, and spirometry was within normal range.
The leg nodules resolved with initial treatment with prednisone
but they recurred along with new nodules when the drug was
withdrawn. She subsequently required prednisone doses ranging
from 10 to 40 mg prednisone a day. In 2009, while on 10 mg
prednisone a day, she developed lupus pernio with painful nodulesughman).
Ltd. This is an open access article uappearing on her cheeks and nose as well as nodules on her fore-
arms. Despite prednisone at 40 mg per day and methotrexate, the
skin lesions were uncontrolled. After a few months with minimal
response, she was started on inﬂiximab and methotrexate was
discontinued because of nausea. The skin lesions improved
gradually.
In 2014 her disease became more complicated when she
developed diffuse muscle achiness and weakness in her legs, arms
and back. The symptoms progressed despite good control of her
skin lesions. Blood testing demonstrated a positive ANAwith a titer
of 1:640 and anti-Jo-1 antibody was present. Screening for other
auto-antibodies including, anti-synthetase antibodies, was nega-
tive. Markedly elevated levels were detected for serum creatinine
phosphokinase (CPK) to 3421 U/L (reference range: 30e223 U/L)
(Fig. 1) and aldolase 27.5 U/L (reference range: 3.3e10.3 U/L). High
resolution CT scan showed no evidence for new or advancing
interstitial lung disease. Positive emission tomography was not
performed. After being diagnosed with inﬂiximab-induced
myositis, inﬂiximab was discontinued, prednisone was increased
to 40mg a day and azathioprine 100mg a daywas prescribed. After
three months, the CPK level decreased to 990 U/L, but the muscle
achiness and weakness did not improve. Patient noted severe side
effects from the high dose prednisone including weight gain,
Cushingoid features, serious sleep disturbances, andmood changes.
The patient started treatment with Acthar gel 80IU twiceweekly
in October 2014, concomitantly with prednisone 15 mg a day and
azathioprine 100 mg a day. After six months of treatment, the skinnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Changes in various features over time with various treatments for sarcoidosis and myositis noted: (A) prednisone dose mg per day change by date; (B) creatinine phos-
phokinase (CPK, U/L); and (C) weight (pounds).
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She no longer experienced any musculoskeletal aches and muscle
strength increased signiﬁcantly. Serum CPK levels decreased to
707 U/L and aldolase normalized at 9 U/L. The patient's steroid side
effects improved after the prednisone dosewas reduced to 10mg/d.
She tolerated Acthar well without any signiﬁcant side effects. In
May 2015, Acthar gel was discontinued for three weeks due to in-
surance issues. Unfortunately, muscle achiness and weakness
recurred and the serum CPK increased to 1449 U/L. Her skin nod-
ules worsened on her legs. Acthar treatments were reinstituted.
After two months, she felt well with muscle symptoms resolved,
skin lesions in near complete remission, and serum CPK reduced to
1041 U/L. At the same time, the prednisone dose was reduced to
5 mg a day, which enabled her to lose an additional 15 pounds. To
date, the patient has otherwise tolerated Acthar gel treatment well.3. Discussion
Sarcoidosis is a systemic disease that is histologically charac-
terized by the formation of noncaseating granulomas in various
organs [4]. The treatment of sarcoidosis is a challenge because theetiology remains unknown. For most patients in whom systemic
treatment is suggested, glucocorticoids remain the initial drugs of
choice [5]. Although some sarcoidosis disease manifestations such
as lupus pernio may respond poorly to glucocorticoids since many
patients cannot tolerate the long-term treatment due to toxicity.
There are several steroid-sparing agents which can be prescribed as
second or third-line therapies. These include cytotoxic agents as
methotrexate or azathioprine, anti-TNF agents as inﬂiximab, or
rituximab [2,6,7].
Inﬂiximab (Remicade) is a chimeric monoclonal antibody
against tumor necrosis alpha (TNF-a), which should be effective in
sarcoidosis because TNF-a can be released bymacrophages in active
sarcoidosis and play a crucial role in the development of the
sarcoidosis granuloma [8]. Inﬂiximab has been reported effective in
patients with both chronic pulmonary sarcoidosis and extra-
pulmonary disease [1,9].
Our patient developed the skin lesions lupus pernio from
sarcoidosis. This disease manifestation is usually considered
chronic and often poorly controlled by usual therapy [10]. Inﬂix-
imab has been reported more effective than glucocorticoids and/or
anti-metabolites in treating lupus pernio [11]. In this case, we found
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had not responded well to high doses of prednisone and prolonged
use of methotrexate. After starting inﬂiximab, the skin lesions
improved for more than 3 years with no further prednisone.
Unfortunately after more than three years on single agent
inﬂiximab, the patient developed a clinical scenario compatible
with drug-inducedmyositis. Anti-TNF drugs have been increasingly
associated with the autoimmune syndromes, including lupus,
vasculitis, and interstitial lung disease [12,13]. Anti-TNF-induced
myositis including anti-Jo-1 antibody has been reported, but is
rare [14e18]. The mechanism of how anti-TNF induced myositis is
inconsistent. The most commonly cited reason is the development
of an autoimmune process [12]. In addition, TNF and its receptors
are overexpressed in myositis, suggesting a contribution of TNF to
the pathogenesis of the disease [19]. However, blocking TNF-a
could lead to disease ﬂares in patients with inﬂammatory myopa-
thies by altering the Th1 and Th2 balance [20,21]. This patient
developed myositis while receiving only inﬂiximab for her
sarcoidosis. She developed new auto antibodies against both ANA
and Jo-1. Both CPK and aldolase levels decreased after discontinu-
ing the treatment. Although the reinstitution of high doses of
prednisone and azathioprine controlled her symptoms, unaccept-
able toxicity developed, including weight gain. This led to the
search for an alternative treatment for the symptoms of both
sarcoidosis and myositis.
Acthar (corticotropin) was the ﬁrst medication approved by the
Food and Drug Administration (FDA) in the United States for the
treatment of sarcoidosis [22,23]. The original sole mechanism of
action was believed to be the stimulation of the adrenal gland to
release glucocorticoids. However, recent studies have demon-
strated that Acthar gel has direct anti-inﬂammatory activities and
immunological effects through stimulating alternative melano-
cortinreceptors (MCRs) [24e26], Several reports demonstrate
Acthar gel efﬁcacy in treating multiple sclerosis and systemic lupus
erythematosus [24,27]. In addition, the drug has been reported
beneﬁcial in treating some cases of advanced sarcoidosis [28].
Levine et al. reported successful treatment of ﬁve patients with
refractory dermatomyositis or polymyositis [29].
This is the ﬁrst report of successful treatment with Acthar gel for
both manifestations of sarcoidosis and inﬂiximab-induced
myositis. We observed resolution of the sarcoidosis skin lesions,
including her lupus pernio. After nine months of Acthar gel use,
improvement in myositis symptoms occurred including musculo-
skeletal aches and muscle strength along with near normalization
of serum CPK and aldolase levels. When Acthar treatment was
discontinued, both muscle symptoms and enzyme levels reboun-
ded which responded to reinstitution of Acthar gel. During the nine
months of treatment, the patient tolerated the drug well without
any side effects, suggesting that this treatment regimen may be
more tolerable than high-dose prednisone. The encouraging result
from this case suggests that Acthar gel should be considered as a
therapy option for sarcoidosis or inﬂiximab induced autoimmune
diseases.
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